WCM
NTLA icon

Wildcat Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Wildcat Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-3,542
Closed -$46K – 18
2016
Q4 		$46K Buy
+3,542
New +$53.2K 0.02% 13
2016
Q3 		– Sell
-25,000
Closed -$534K – 27
2016
Q2 		$534K Buy
+25,000
New +$665K 0.2% 17

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Wildcat Capital Management's NTLA Position: Q1 2017 in Review

Wildcat Capital Management sold out of Intellia Therapeutics (NTLA) in Q1 2017, closing a stake of 3,542 shares — an estimated $46K sold.

Wildcat Capital Management first reported a position in NTLA in Q2 2016 and held it in 2 quarters. The position peaked at $534K in Q2 2016. 76 funds tracked by Wall St. Rank hold NTLA as of Q1 2017.

  • Wildcat Capital Management reported no remaining Intellia Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Wildcat Capital Management sold 3,542 Intellia Therapeutics shares in Q1 2017, an estimated $46K.
  • Wildcat Capital Management first reported a position in Intellia Therapeutics in Q2 2016 and held it in 2 quarters.
  • Wildcat Capital Management's Intellia Therapeutics position peaked at $534K in Q2 2016.
  • 76 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2017.

Based on Wildcat Capital Management's 13F filing for Q1 2017, filed 9 May 2017.